Datar Cancer Genetics Gains CE Mark for Cancer Diagnostic
Datar Cancer Genetics’ TruBlood, a blood-based test used to evaluate suspected cases of cancer that have been recommended for biopsy, has earned the CE mark.
The noninvasive test assesses the presence of circulating clusters of tumor cells called C-ETACS (circulating ensembles of tumor-associated cells), which have been found to be prevalent in the blood of cancer patients and undetectable in those who are cancer-free.
The blood test can help individuals with suspicious growths in the lung, breast, prostate, brain or colon to avoid invasive biopsies. It can also help in the diagnosis of cases where invasive biopsies cannot be done, such as when a tumor is close to a vital organ or blood vessel or when the patient has co-morbidities.